CoreTissue BioEngineering develops tissue-engineered ligaments using a proprietary decellularization technology for anterior cruciate ligament (ACL) reconstruction. This approach addresses the need for effective regeneration of damaged ligaments, enabling athletes to return to peak performance.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Anterior cruciate ligament (ACL) injuries are common, particularly among athletes, and current reconstruction techniques often fail to fully restore native ligament function, leading to long recovery times and potential for re-injury. Existing solutions may not adequately promote tissue regeneration, hindering athletes' return to peak performance.
Solution
CoreTissue BioEngineering (CTBE) develops tissue-engineered ligaments for ACL reconstruction using a proprietary decellularization technology. This approach aims to regenerate damaged ligaments, facilitating a more complete and functional recovery. The decellularization process removes cells from donor tissue while preserving the extracellular matrix, providing a scaffold for the patient's own cells to repopulate and regenerate a functional ligament. CTBE's tissue-engineered ligaments are designed to improve the speed and quality of healing, enabling athletes to return to their pre-injury performance levels.
Target Audience
The primary target audience includes athletes with ACL injuries and orthopedic surgeons specializing in sports medicine and ligament reconstruction.
Features
- Tissue-engineered ligaments created using a proprietary decellularization process
- Designed to promote regeneration of damaged ACL tissue
- Aims to restore native ligament function more effectively than traditional methods